Re: Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther. 2003;25:105-118. - Suppr | 超能文献

Re: Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther. 2003;25:105-118.

作者信息

Durelli Luca, Verdun Elisabetta, Barbero Pierangelo, Bergui Mauro, Versino Elisabetta

出版信息

Clin Ther. 2003 Jun;25(6):1890-3. doi: 10.1016/s0149-2918(03)90054-3.

DOI:10.1016/s0149-2918(03)90054-3

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Re: Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther. 2003;25:105-118.

Clin Ther. 2003 Jun;25(6):1890-3. doi: 10.1016/s0149-2918(03)90054-3.

2

Re: Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther. 2003;25:105-118.

Clin Ther. 2003 Jun;25(6):1888-90. doi: 10.1016/s0149-2918(03)90030-0.

3

An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis.

Clin Ther. 2003 Jan;25(1):105-18. doi: 10.1016/s0149-2918(03)90013-0.

4

Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis.

BioDrugs. 2005;19(5):323-5. doi: 10.2165/00063030-200519050-00005.

5

Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article].

Neurology. 2001 Dec;57(12 Suppl 5):S10-5.

6

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997.

Neurology. 2001 Dec;57(12 Suppl 5):S25-30.

7

Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.

Mult Scler. 2000 Dec;6(6):365-72. doi: 10.1177/135245850000600601.

8

Acute demyelinating disease after interferon beta-1a treatment for multiple sclerosis.

Neurology. 2000 Nov 14;55(9):1416-7. doi: 10.1212/wnl.55.9.1416.

9

Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis.

Drugs. 2005;65(9):1295-312. doi: 10.2165/00003495-200565090-00010.

10

Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.

BMC Neurol. 2018 Sep 14;18(1):143. doi: 10.1186/s12883-018-1145-x.

引用本文的文献

1

Is multiple sclerosis a disease that requires frequent beta interferon dosing?

J Neurol. 2004 Sep;251 Suppl 4:IV13-24. doi: 10.1007/s00415-004-1404-1.